Glenmark Pharmaceuticals Limited

As of June 30, 2026, Glenmark Pharmaceuticals Limited carries a market capitalization of 622.05B, placing it among publicly traded companies globally. Its enterprise value stands at 622.05B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Glenmark Pharmaceuticals Limited's next confirmed earnings release is scheduled for November 6, 2026.

As of June 30, 2026, Glenmark Pharmaceuticals Limited has 282.20M shares outstanding.

As of June 30, 2026, Glenmark Pharmaceuticals Limited trades at a trailing price-to-earnings ratio of 34.60.

As of June 30, 2026, Glenmark Pharmaceuticals Limited trades at an EV/EBITDA multiple of 21.80 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.54 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 27.81 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 622.05B versus a market cap of 622.05B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 10.22M in revenue per employee across its workforce of 17,202.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Glenmark Pharmaceuticals Limited recorded 7.35B in income tax expense. That works out to an effective tax rate of 29.01, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 25.33B, leaving 17.98B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Glenmark Pharmaceuticals Limited's stock has gained approximately 18.49% over the past 52 weeks. The 50-day moving average sits at 2,359.29, while the 200-day moving average is 2,217.00.

Over the twelve months ended June 30, 2026, Glenmark Pharmaceuticals Limited generated 175.84B in revenue and converted that into 17.98B in net income, yielding earnings per share of 63.69. EBITDA reached 28.54B, while operating income came in at 41.80B.

Over the twelve months ended June 30, 2026, Glenmark Pharmaceuticals Limited posted a gross margin of 71.69, reflecting its pricing power and cost economics. The operating margin of 23.77 and net profit margin of 10.22 provide insight into operational efficiency.

Glenmark Pharmaceuticals Limited's most recent stock split took place on September 10, 2007 with a 1:2 split ratio.